Evaluation of the Efficacy and Safety of Nano-S1 (COVNANOS1)
COVID-19 Pneumonia
About this trial
This is an interventional treatment trial for COVID-19 Pneumonia focused on measuring ARGENT COLLOIDAL
Eligibility Criteria
Inclusion Criteria: Participants are hospitalized in a COVID unity or outpatient follow-up by the investigator Participants who have positive SARS-CoV-2 test result and the onset of symptoms of COVID-19 ≤7 days prior to randomization, Not exceed the 7th day since the beginning of disease symptoms; and the randomization's day. Present at least one of these symptoms: Participants who have one or more mild or moderate COVID-19 symptoms: Fever, general signs such as: headaches, asthenia, myalgia, arthralgia, etc... ENT signs such as: Sore throat, anosmia, agueusia, hypoacusis, deafness, etc... Digestive signs such as: diarrhea, vomiting, abdominal pain, etc... Respiratory signs such as: dyspnea, cough, etc... And cutaneous signs such as: skin rash, livedo, etc... Present an oxygen saturation patients with SpO2 > 94% at room air Present at least one of these risk factors: Participants who satisfy one or more than one of the following high risks for progression to severe COVID-19, including death: Age 65 years old Or -Age between 18 and 64 years old with at least one of these risk factors: Obesity (BMI> 30 kg/m2),and/or diabetes under treatment and/or cardiovascular disease (including hypertension and stable angina) high blood pressure and/or Chronic obstructive pulmonary disease (COPD) disease and/or asthma and/or Neoplasia (solid tumour; hematological malignancy) neoplasia, and/or a blood disease and/or heart failure and/or chronic renal failure (Cl creat> 30Mml/min) and/or unstabe angina and/or autoimmune disease. Have signed the informed consent to participate in this trial. Exclusion Criteria: Non observance.Non-compliant patient With drawal of Consent. Patient who refuses blood samples.
Sites / Locations
- Agili Faida
Arms of the Study
Arm 1
Arm 2
Experimental
Placebo Comparator
A bras actif
B bras controle
The experimental arm has received the Nanos product orally with a dose of 30mL, 3 times per day and away from meals (2 hours after a meal or on an empty stomach).
The placebo arm has received the Nanos product orally with a dose of 30mL, 3 times per day and away from meals (2 hours after a meal or on an empty stomach).